(-0.41%) 5 460.48 points
(-0.12%) 39 119 points
(-0.71%) 17 733 points
(-0.34%) $81.46
(-3.13%) $2.60
(0.01%) $2 336.90
(0.61%) $29.44
(0.28%) $1 009.00
(-0.06%) $0.933
(0.45%) $10.68
(-0.05%) $0.791
(0.86%) $85.73
Live Chart Being Loaded With Signals
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally...
Stats | |
---|---|
आज की मात्रा | 2 200 |
औसत मात्रा | 1 903 |
बाजार मूल्य | 491.52M |
EPS | $0.220 ( Q2 | 2023-12-31 ) |
अगली कमाई की तारीख | ( $0 ) 2024-08-26 |
Last Dividend | $0.0320 ( 2023-09-07 ) |
Next Dividend | $0 ( N/A ) |
P/E |
25.82 (Sector) 0 (Industry) 0 |
ATR14 | $0 (0.00%) |
Clinuvel Pharmaceuticals सहसंबंध
10 सबसे अधिक सकारात्मक सहसंबंध |
---|
10 सबसे अधिक नकारात्मक सहसंबंध |
---|
क्या आप जानते हैं?
कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।
कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।
Clinuvel Pharmaceuticals वित्तीय
Annual | 2023 |
राजस्व: | $78.32M |
सकल लाभ: | $50.59M (64.59 %) |
EPS: | $0.620 |
FY | 2023 |
राजस्व: | $78.32M |
सकल लाभ: | $50.59M (64.59 %) |
EPS: | $0.620 |
FY | 2022 |
राजस्व: | $65.72M |
सकल लाभ: | $46.62M (70.93 %) |
EPS: | $0.420 |
FY | 2021 |
राजस्व: | $47.98M |
सकल लाभ: | $43.26M (90.16 %) |
EPS: | $0.502 |
Financial Reports:
No articles found.
Clinuvel Pharmaceuticals Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0.0270 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0.0320 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.0140 | 2018-09-20 |
Last Dividend | $0.0320 | 2023-09-07 |
Next Dividend | $0 | N/A |
Payout Date | 2023-10-02 | |
Next Payout Date | N/A | |
# dividends | 6 | -- |
Total Paid Out | $0.126 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.23 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 7.45 | |
Div. Directional Score | 8.90 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Furthermore, its high Dividend Growth Potential Score (DGPS) signals potential dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Ex Date | Amount | Declaration Date | Record Date | Payment Date |
---|---|---|---|---|
07 Sep 2023 | $0.0320 | 30 Aug 2023 | 08 Sep 2023 | 02 Oct 2023 |
09 Sep 2022 | $0.0270 | 02 Sep 2022 | 12 Sep 2022 | 03 Oct 2022 |
03 Sep 2021 | $0.0180 | 01 Sep 2021 | 06 Sep 2021 | 27 Sep 2021 |
04 Sep 2020 | $0.0180 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
06 Sep 2019 | $0.0170 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
20 Sep 2018 | $0.0140 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
YATRF | Ex Dividend Junior | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
HAWPY | Ex Dividend Knight | 2023-08-22 | Semi-Annually | 0 | 0.00% | |
SNMCY | Ex Dividend Junior | 2023-08-18 | Semi-Annually | 0 | 0.00% | |
CSLLY | Ex Dividend Knight | 2023-09-08 | Semi-Annually | 0 | 0.00% | |
NHMD | Ex Dividend Junior | 2023-08-30 | Semi-Annually | 0 | 0.00% | |
BBBK | Ex Dividend Knight | 2023-09-18 | Quarterly | 0 | 0.00% | |
IMBBY | Ex Dividend Knight | 2023-08-17 | Quarterly | 0 | 0.00% | |
UBEOF | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
FABP | Ex Dividend Knight | 2023-07-31 | Quarterly | 0 | 0.00% | |
PRNDY | Ex Dividend Knight | 2023-06-30 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.371 | 1.500 | 2.58 | 3.86 | [0 - 0.5] |
returnOnAssetsTTM | 0.142 | 1.200 | 5.25 | 6.30 | [0 - 0.3] |
returnOnEquityTTM | 0.176 | 1.500 | 9.16 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.0819 | -1.000 | 9.18 | -9.18 | [0 - 1] |
currentRatioTTM | 6.86 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 6.38 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 1.321 | 1.500 | 3.77 | 5.66 | [0.2 - 2] |
debtRatioTTM | 0.00505 | -1.500 | 9.92 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | -1.111 | -1.111 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.843 | 2.00 | 9.72 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.725 | 2.00 | 9.64 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.00598 | -1.500 | 9.98 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.621 | 1.000 | 2.99 | 2.99 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.483 | 1.000 | 2.33 | 2.33 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 39.55 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.384 | 0.800 | -0.775 | -0.620 | [0.5 - 2] |
Total Score | 10.36 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 24.45 | 1.000 | 7.63 | 0 | [1 - 100] |
returnOnEquityTTM | 0.176 | 2.50 | 9.46 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.725 | 2.00 | 9.76 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0.218 | 1.500 | 4.56 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.843 | 2.00 | 9.72 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.0819 | 1.500 | 9.18 | -9.18 | [0 - 1] |
pegRatioTTM | 0.602 | 1.500 | 9.32 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.520 | 1.000 | 10.00 | 0 | [0.1 - 0.5] |
Total Score | 7.45 |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Clinuvel Pharmaceuticals
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke increased and prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.
के बारे में लाइव सिग्नल्स
इस पृष्ठ पर प्रस्तुत लाइव सिग्नल्स NA को कब खरीदना या बेचना है, इसका निर्धारण करने में मदद करते हैं। सिग्नल्स में 1-मिनट की देरी हो सकती है; सभी बाजार सिग्नल्स की तरह, त्रुटि या गलतियों की संभावना होती है।
लाइव ट्रेडिंग सिग्नल्स स्थायी नहीं हैं, और getagraph.com इन सिग्नल्स पर किए गए किसी भी कार्रवाई के लिए जिम्मेदारी नहीं रखते हैं, जैसा कि उपयोग की शर्तें में वर्णित है। सिग्नल्स एक व्यापक श्रृंखला के तकनीकी विश्लेषण संकेतकों पर आधारित हैं